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Multisystem Inflammatory Syndrome in Children –
Characteristics, Therapies, and Outcomes
Reid A. Sindelar1, Dr. Angela T. Yetman2,3, Dr. Jean A. Ballweg2,3
Joint Division of Pediatric Cardiology, University of Nebraska Medical Center2; Children’s Hospital and Medical Center3; University of Oklahoma1
Multisystem Inflammatory Syndrome in Children (MIS-C) is a 
condition characterized by severe systemic inflammation and shock, 
presenting approximately 4-6 weeks following infection with SARS-CoV-21. 
This emerging disease is identified by the presence of prolonged fever, 
elevated inflammatory markers, involvement of several organ systems, and 
evidence of recent COVID-19 infection in pediatric patients2. The risk 
factors for developing MIS-C as well as the long-term outcomes for patients 
with MIS-C are still unclear.
Objectives
•Identify demographic trends to better predict who is at risk of developing
MIS-C following SARS-CoV-2 infection
•Identify symptoms, complications, and effective treatment methods
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Background
Methods
We performed a single-center retrospective cohort study of pediatric 
patients <21 years of age who presented with MIS-C between April 2020 
and June 2021. A variety of data was collected on these patients, including:
•Demographics such as age, gender, race & ethnicity
•Existing comorbidities
•Clinical course
•Lab values and scans
•Medications and treatments
•Patient outcomes following hospital discharge, up to 1 year
The data was analyzed to identify significant trends in patient type, disease 
presentation, and outcome. The data was also entered into a secure shared 
database to be used in further study through the IKDR and the 
































































SD = systolic dysfunction
DD = diastolic dysfunction
CA = coronary abnormality
Cardiac Complications Associated with MIS-C
Dysfunction Normal Function
Admission 3 months 6 months 12 months
Table 1 Laboratory Findings & Biological Parameters
Median (Min – Max) Normal Laboratory Values
Troponin-I (mg/mL) 0.048 (0.013 - 67.4) < 0.013 mg/mL
Pro-BNP (pg/mL) 4510 (22 - 28000) < 391 pg/mL
ESR 63 (10 - 120) < 15 mm/hr
C-reactive protein 148 (18.5 - 270) < 0.7 mg/dL
D-dimer 4274 (534 - 35709) < 500 ng/mL
Fibrinogen 502 (213 - 1000) < 335 mg/dL
Ferritin 356.5 (69- 5677) < 300 ng/mL
Sodium 132 (118 - 139) > 134 mmol/L
Patients with abnormal Troponin-I – n (%) 39 (68.4) -
Patients with abnormal pro-BNP – n (%) 49 (86) -
Patients with AKI* - n (%) 17 (29.8) -
pro-BNP, pro-brain natriuretic peptide; ESR, erythrocyte sedimentation rate; AKI, acute kidney injury
*AKI is determined by doubling of creatinine values during hospital course
Results
Table 2 Hospital Treatment of MIS-C 
Patients
IVIG – n (%) 55 (96)
1 dose 23 (40)
> doses 32 (56)
Antiplatelets 53 (93)
Anticoagulants 55 (96)
IV steroid 41 (72)
Oral steroid 39 (68)






Antiplatelets = aspirin, IV steroid = methylprednisolone, 
Oral steroid = prednisolone, IL blocker = Anakinra 
Table 3 Hospital Course
Length of hospital stay (days) -
median (r,stdev)
5 (3-22,12)
ICU admission* - n (%) 26 (46)






Supplemental oxygen – n (%) 9 (16)
Mechanical ventilation – n (%) 8 (14)
Extracorporeal membrane              
oxygenation – n (%)
1 (1.7)
Arrhythmia – n (%) 2 (3.5)
Discharged alive – n (%) 57 (100)




























• Development of MIS-C is more likely in pediatric patients who are male, 
Hispanic/Latino, and overweight or obese.
• MIS-C symptoms are myriad but most commonly present as prolonged fever, 
abdominal pain, and vomiting.
• Key lab values for MIS-C include elevated Troponin-I and pro-BNP, suggesting 
high prevalence of cardiac involvement.
• The use of IVIG, antiplatelets, and anticoagulants may decrease incidence of 
prolonged coronary dilation, decrease inflammatory markers, and decrease renal 
dysfunction and presenting symptoms.
• Nearly all cardiac complications associated with MIS-C resolve 3-6 months after 
discharge.
19%
28%
53%
WEIGHT DISTRIBUTION
Overweight
Obese
Normal Weight
